NuVasive - NUVA Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued 12 month price objectives for NuVasive's shares. Their NUVA share price forecasts range from $54.00 to $83.00. On average, they predict the company's stock price to reach $61.91 in the next year. This suggests a possible upside of 15.7% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $52.48 at the beginning of 2022. Since then, NUVA stock has increased by 1.9% and is now trading at $53.49.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our NUVA earnings forecast.

NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Tuesday, November, 9th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.54 by $0.22. The medical device company had revenue of $270.84 million for the quarter, compared to analyst estimates of $291.32 million. NuVasive had a negative net margin of 3.41% and a positive trailing twelve-month return on equity of 11.12%. During the same period in the previous year, the company posted $0.54 EPS.

NuVasive declared that its Board of Directors has approved a stock buyback program on Tuesday, November 9th 2021, which allows the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.5% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its shares are undervalued.

NuVasive updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of $2.15-$2.45 for the period, compared to the consensus EPS estimate of $2.31. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.22 billion.

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive's stock is owned by many different retail and institutional investors. Top institutional shareholders include Paradice Investment Management LLC (2.28%), Loomis Sayles & Co. L P (1.57%), Stephens Investment Management Group LLC (1.54%), Northern Trust Corp (1.35%), Frontier Capital Management Co. LLC (1.32%) and Victory Capital Management Inc. (1.25%). Insiders that own company stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock.
View institutional ownership trends.

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $53.49.

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.78 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

The company employs 2,900 workers across the globe.

NuVasive was founded in 1997.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.